glp 1 parch GLP-1 Nano Patch, Firming Skin and Body Care Patch, with Ginger Extract for Women 30 Count GLP-1 meds changed the game

Among those who used a GLP-1 or GLP-1/GIP medication to support weight loss within the previous year, 15% reported using a medication that was not licensed for weight loss in the UK

Current NHS eligibility criteria for semaglutide 2.4 mg (Wegovy) for weight management, according to NICE TA875, include: Body Mass Index (BMI) 35 kg/m with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea) For people from certain high-risk ethnic groups (such as South Asian, Chinese, Black African, or African-Caribbean), lower BMI thresholds apply (typically reduced by 2.5 kg/m) Treatment must be prescribed within specialist weight management services only Treatment is limited to a maximum duration of 2 years Must be used as an adjunct to a reduced-calorie diet and increased physical activity Liraglutide 3 mg (Saxenda) availability varies significantly across NHS regions and is not routinely commissioned in many areas

Liakos A, Karagiannis T, Athanasiadou E, Sarigianni M, Mainou M, Papatheodorou K, et al

Still, gastrointestinal issues like vomiting or diarrhea may lead to severe dehydration, which acutely stresses the kidneys

The challenge is clear: reformulate to align with these new consumer priorities in a rapidly changing market

doi: 10.3390/molecules27041351